Author: Xu, Kun; Dai, Lianpan; Gao, George F
Title: Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021 Cord-id: gallrb6p Document date: 2021_9_7
ID: gallrb6p
Snippet: Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity
Document: Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.
Search related documents:
Co phrase search for related documents- adaptive innate and adenovirus vaccine: 1, 2, 3
- adaptive innate and lymphocyte response: 1, 2, 3, 4, 5, 6
- adaptive innate immune response and lymphocyte response: 1, 2, 3
- adenovirus vaccine and lymphocyte response: 1
- adjuvant addition and lymphocyte response: 1
Co phrase search for related documents, hyperlinks ordered by date